Compare DLNG & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLNG | ZNTL |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.0M | 156.7M |
| IPO Year | N/A | 2020 |
| Metric | DLNG | ZNTL |
|---|---|---|
| Price | $3.92 | $2.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 94.5K | ★ 614.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | N/A | ★ 47.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,425,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.37 | N/A |
| P/E Ratio | $3.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $1.01 |
| 52 Week High | $4.27 | $3.95 |
| Indicator | DLNG | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 50.97 | 46.91 |
| Support Level | $3.46 | $1.27 |
| Resistance Level | $3.97 | $2.69 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 41.67 | 32.29 |
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.